Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 6 open reading frame 132 (C6orf132) is an uncharacterized gene that encodes a predicted long noncoding RNA (lncRNA) also referred to as LncCCLM or "cervical cancer lymphatic metastasis-associated lncRNA." Recent research indicates that altered expression of C6orf132 may be associated with lymphatic metastasis and poor prognosis in cervical cancer patients, suggesting a role in cancer progression[5][8][9]. Its specific molecular function and mechanism remain uncharacterized; there are no established therapeutic drugs known to target it, nor has it been validated as a classical therapeutic target (e.g., receptor, enzyme, transporter, etc.)[9]. While its utility is currently limited to biomarker research, further studies are required to elucidate its biological and therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 6 open reading frame 132 (C6orf132).